Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 1997 Nov 17;186(10):1725–1735. doi: 10.1084/jem.186.10.1725

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

The effect of anti-α₆ integrin antibody EA-1 and GRGDS peptide on the migration of epidermal LCs in vitro. Skin explants were incubated on culture medium containing: (A) 50 μg/ml EA-1 (solid bars) or control antibody (hatched bars); (B) 500 μM GRGDS (RGD; solid bars) or GRDGS (RDG; hatched bars). Additional controls included explants incubated on medium containing no antibody (open bars). The number of LCs/ mm² was determined after 24 and 72 h of incubation and compared with fresh skin (0 h). Results are expressed as means ± SD (n = 18). Treatment of explant cultures with EA-1 antibody failed to cause a significant increase in the frequency of LCs at 24 or 72 h compared with cultures containing no antibody or an isotype-matched control antibody (A). Addition to explant cultures of GRGDS also failed to cause a significant increase in the frequency of LCs at 24 or 72 h compared with cultures containing no peptide or GRDGS.